Januvia and Janumet are two of Merck & Co.'s (MRK) blockbuster drugs in its diabetes franchise. They're used to lower blood sugar levels in patients with type 2 diabetes. The combined sales for these drugs were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.
Chart - 006 - JJ
Uses for Januvia and Janumet
Januvia and Janumet, its combination version, are drugs classified as DPP-4 inhibitors. DPP-4 is the enzyme dipeptidyl peptidase-4, which removes incretin from the human body in people without type 2 diabetes. However, people with type 2 diabetes require these DPP-4 inhibitors to prevent low blood sugar and sometimes control weight gain.
Januvia has a very high share in Japan. DPP-4 inhibitors have more patient days of
Chart - 006 - JJ
Uses for Januvia and Janumet
Januvia and Janumet, its combination version, are drugs classified as DPP-4 inhibitors. DPP-4 is the enzyme dipeptidyl peptidase-4, which removes incretin from the human body in people without type 2 diabetes. However, people with type 2 diabetes require these DPP-4 inhibitors to prevent low blood sugar and sometimes control weight gain.
Januvia has a very high share in Japan. DPP-4 inhibitors have more patient days of